Immunomodulatory peptides derived from Japanese rice
|
Categories |
Peptide, Small Molecule, Inflammatory/Autoimmune diseases |
|
Development Stage |
Proof of concept in MS mouse model |
|
Patent Status |
Patent filed in the United States |
|
Market |
Worldwide, the incidence of multiple sclerosis (MS) is approximately 0.1%. The market for MS has total global revenues of over $6 billion. |
Highlights
-
Two peptides, termed IIIM1 and RA1,have found to be active in ameliorating MS symptoms in animals
-
One of these peptides, RA1, is also found in Japanese rice ( Oryza Sativa Japonica group) may be involved in the low prevalence and incidence of MS in Chinese and Japanese populations.
-
Current MS treatments are of limited efficacy and have severe/unpleasant side effects.
-
Initial toxicity tests have not revealed any side effects.
Our Innovation
-
Two synthetic peptides have found to be effective for treating or protecting against inflammatory conditions or diseases, including multiple sclerosis (MS).
Key Features
-
The two peptides are easily synthesized and can be delivered orally.
-
RA1 can be delivered both orally and intraperitoneally
-
RA1 is a naturally-occurring peptide found in Japanese rice and will thus require less stringent toxicology tests for FDA approval
Development Milestones
-
Toxicity studies, clinical trials
The Opportunity
-
Applications in the treatment of other inflammatory diseases, autoimmune diseases, and diseases associated with free radicals
-
The peptides may be used as treatments and also as adjuvants to other treatments.
1586128900.png)